GSK reports positive results from depemokimab trial

11:08, 14th October 2024
Vox News
Vox News
Company News
TwitterFacebookLinkedIn

    has announced positive results from a phase III trial of its depemokimab treatment for chronic rhinosinusitis with nasal polyps (CRSwNP).
The pharma giant said on Monday that the ANCHOR-1 and ANCHOR-2 trials, which assessed the efficacy and safety of depemokimab compared with a placebo, both met their co-primary endpoints.

The trials found a statistically significant reduction in both patients' nasal polyp size and nasal obstruction compared with the placebo after a year of treatment.

Depemokimab, which is administered once every six months, is the first ultra-long-acting biologic to be evaluated in phase II trials. It is hoped to treat the millions of people worldwide - estimated at 4% of the general population - that suffer from CRSwNP, experiencing things like nasal obstruction, loss of smell, facial pressure, sleep disturbance, infections and nasal discharge.

"We're very encouraged by the results from the ANCHOR studies, which demonstrate the potential for depemokimab to offer targeted and sustained suppression of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction," said Kaivan Khavandi, senior vice president, global head of respiratory and immunology R&D at GSK.

"Today's data, along with recent phase III data in severe asthma, will be used in regulatory filings around the world."

The stock was up 1% at 1,494.5p by 0854 BST.

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Watchlist